Integrated Investment Consultants’s Thermo Fisher Scientific TMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $201K | Sell |
400
-78
| -16% | -$37.4K | 0.04% | 262 |
|
|
2026
Q1 | $235K | Sell |
478
-2
| -0.4% | -$1.08K | 0.05% | 233 |
|
|
2025
Q4 | $278K | Buy |
480
+27
| +6% | +$15.3K | 0.05% | 211 |
|
|
2025
Q3 | $220K | Buy |
+453
| New | +$211K | 0.04% | 302 |
|
|
2025
Q2 | – | Sell |
-1,001
| Closed | -$498K | – | 363 |
|
|
2025
Q1 | $498K | Sell |
1,001
-8
| -0.8% | -$4.33K | 0.1% | 154 |
|
|
2024
Q4 | $525K | Hold |
1,009
| – | – | 0.11% | 149 |
|
|
2024
Q3 | $624K | Buy |
1,009
+257
| +34% | +$152K | 0.14% | 116 |
|
|
2024
Q2 | $437K | Hold |
752
| – | – | 0.12% | 140 |
|
|
2024
Q1 | $437K | Buy |
752
+169
| +29% | +$94.8K | 0.12% | 140 |
|
|
2023
Q4 | $309K | Buy |
583
+93
| +19% | +$45K | 0.1% | 181 |
|
|
2023
Q3 | $248K | Sell |
490
-160
| -25% | -$85.3K | 0.09% | 193 |
|
|
2023
Q2 | $339K | Buy |
650
+84
| +15% | +$45.3K | 0.11% | 169 |
|
|
2023
Q1 | $326K | Buy |
+566
| New | +$319K | 0.1% | 182 |
|
|
2022
Q2 | – | Sell |
-641
| Closed | -$378K | – | 299 |
|
|
2022
Q1 | $378K | Sell |
641
-178
| -22% | -$102K | 0.1% | 180 |
|
|
2021
Q4 | $546K | Sell |
819
-269
| -25% | -$168K | 0.15% | 120 |
|
|
2021
Q3 | $622K | Buy |
1,088
+22
| +2% | +$12.1K | 0.18% | 99 |
|
|
2021
Q2 | $538K | Sell |
1,066
-118
| -10% | -$55.7K | 0.16% | 116 |
|
|
2021
Q1 | $541K | Sell |
1,184
-150
| -11% | -$71.6K | 0.19% | 102 |
|
|
2020
Q4 | $622K | Sell |
1,334
-18
| -1% | -$8.44K | 0.23% | 83 |
|
|
2020
Q3 | $597K | Hold |
1,352
| – | – | 0.28% | 66 |
|
|
2020
Q2 | $490K | Hold |
1,352
| – | – | 0.23% | 73 |
|
|
2020
Q1 | $383K | Hold |
1,352
| – | – | 0.23% | 82 |
|
|
2019
Q4 | $439K | Sell |
1,352
-65
| -5% | -$19.7K | 0.18% | 86 |
|
|
2019
Q3 | $413K | Sell |
1,417
-168
| -11% | -$48.1K | 0.21% | 85 |
|
|
2019
Q2 | $465K | Sell |
1,585
-63
| -4% | -$17.4K | 0.24% | 76 |
|
|
2019
Q1 | $451K | Hold |
1,648
| – | – | 0.24% | 74 |
|
|
2018
Q4 | $369K | Buy |
1,648
+168
| +11% | +$39.4K | 0.2% | 83 |
|
|
2018
Q3 | $361K | Sell |
1,480
-7
| -0.5% | -$1.61K | 0.18% | 84 |
|
|
2018
Q2 | $308K | Sell |
1,487
-625
| -30% | -$133K | 0.16% | 93 |
|
|
2018
Q1 | $436K | Buy |
+2,112
| New | +$443K | 0.17% | 80 |
|
|
2017
Q3 | $295K | Buy |
1,560
+10
| +0.6% | +$1.81K | 0.13% | 98 |
|
|
2017
Q2 | $270K | Sell |
1,550
-150
| -9% | -$25.2K | 0.12% | 106 |
|
|
2017
Q1 | $261K | Hold |
1,700
| – | – | 0.12% | 109 |
|
|
2016
Q4 | $24K | Hold |
1,700
| – | – | 0.01% | 439 |
|
|
2016
Q3 | $258K | Hold |
1,700
| – | – | 0.13% | 100 |
|
|
2016
Q2 | $251K | Hold |
1,700
| – | – | 0.14% | 102 |
|
|
2016
Q1 | $242K | Hold |
1,700
| – | – | 0.14% | 99 |
|
|
2015
Q4 | $230K | Buy |
+1,700
| New | +$227K | 0.18% | 93 |
|
Other funds holding TMO
Integrated Investment Consultants's TMO Position: Q2 2026 in Review
Integrated Investment Consultants reduced its Thermo Fisher Scientific (TMO) stake by 16% in Q2 2026, selling an estimated $37.4K and leaving 400 shares worth $201K. The position accounts for 0.04% of the portfolio, ranked #262.
Integrated Investment Consultants first reported a position in TMO in Q4 2015 and has held it in 38 quarters since. The position peaked at $624K in Q3 2024. 2,609 funds tracked by Wall St. Rank hold TMO as of Q2 2026.
- Integrated Investment Consultants held 400 shares of Thermo Fisher Scientific worth $201K as of Q2 2026.
- Integrated Investment Consultants sold 78 Thermo Fisher Scientific shares in Q2 2026, an estimated $37.4K.
- Thermo Fisher Scientific made up 0.04% of Integrated Investment Consultants's portfolio in Q2 2026, its #262 holding.
- Integrated Investment Consultants first reported a position in Thermo Fisher Scientific in Q4 2015 and has held it in 38 quarters since.
- Integrated Investment Consultants's Thermo Fisher Scientific position peaked at $624K in Q3 2024.
- 2,609 funds tracked by Wall St. Rank held Thermo Fisher Scientific as of Q2 2026.
Based on Integrated Investment Consultants's 13F filing for Q2 2026, filed 17 Aug 2026.